7 Best Peptides for Frailty

What to Know Before Choosing a Peptide for Frailty

Frailty is not a single problem. It is a cluster of age-related changes happening at once: progressive muscle loss, declining growth hormone output, slower tissue repair, rising chronic inflammation, and a metabolic system that runs less efficiently year by year. That complexity is why the peptide conversation around frailty is wide. Different compounds target different parts of the picture, and the people using them are usually trying to address one or two specific components rather than frailty as an abstract diagnosis.

A compound earns a place on this list because people use it for frailty-related goals, or are actively discussing using it. That is the only entry requirement. FDA-approved compounds belong here, and so do telemedicine-prescribed peptides, research-only compounds, and anything with only community-reported use behind it. Evidence strength is stated honestly inside each entry and is never used as a filter for whether a compound appears at all. A widely-used compound with thin published data still earns its slot, with that thin evidence described plainly.

The seven entries below are numbered by how prominently each compound appears in research and documented real-world use for frailty, not as a recommendation that one is better than another for any particular person. The number in front of an entry is a position in a list, nothing more. What fits your situation depends on your health history, your specific goals, and what a qualified clinician helps you decide. No dose numbers appear anywhere in this guide; that level of detail belongs in a personalized plan, not a public overview.

1. MK-677: For Rebuilding the GH/IGF-1 Axis

MK-677, also called ibutamoren, sits at the top of the frailty conversation because it targets one of the most measurable drivers of age-related decline: the slow collapse of growth hormone output that happens as people age, a process sometimes called somatopause. It is technically not a peptide but a non-peptide ghrelin receptor agonist, meaning it mimics ghrelin, the hunger and growth hormone signaling molecule, by binding to the ghrelin receptor in the brain and pituitary. The result is a sustained increase in endogenous growth hormone and, downstream, IGF-1, the signaling protein that actually drives protein synthesis and muscle maintenance.

What makes MK-677 stand out in this field is that it is taken orally. Every other compound on this list requires injection. That practical advantage, combined with a roughly 24-hour half-life that allows once-daily dosing, has made it one of the most consistently used compounds in longevity and anti-aging communities for people who want to address sarcopenia and sleep quality without needles.

The human evidence here is real, which cannot be said for every entry on this list. Studies in older adult populations have shown that MK-677 can increase lean body mass and raise GH and IGF-1 levels. Research has also examined effects on sleep architecture, particularly slow-wave sleep, which is the phase most associated with overnight recovery and natural growth hormone release. Published work on bone mineral density adds relevance to the osteoporosis component of frailty.

The safety picture matters as much as the evidence of benefit. MK-677 increases appetite and causes water retention, and it has a real effect on fasting blood glucose and insulin sensitivity. For older adults already managing pre-diabetes or metabolic dysfunction, that is a meaningful concern. Sustained elevation of IGF-1 also carries theoretical long-term questions that have not been fully resolved in large human studies. It is not FDA-approved and is classified as a research chemical, with its regulatory future under active discussion.

2. CJC-1295: For Sustained GH Stimulation

CJC-1295 is a synthetic analog of growth hormone releasing hormone, the peptide the hypothalamus naturally uses to signal the pituitary to release growth hormone. Where MK-677 works by mimicking ghrelin, CJC-1295 works upstream at the GHRH receptor on pituitary cells specifically responsible for producing and releasing GH.

It comes in two versions that behave quite differently. The DAC version, which stands for Drug Affinity Complex, binds to albumin in the bloodstream after injection, extending its active half-life from a matter of minutes to roughly six to eight days. The version without DAC, sometimes called Modified GRF 1-29, has a shorter window and produces more pulse-like GH release that more closely resembles natural physiology. Community use heavily favors stacking the without-DAC version with Ipamorelin, which targets a different receptor and adds to GH stimulation through a complementary pathway.

Human clinical trials have shown that CJC-1295 with DAC produces sustained, measurable increases in GH and IGF-1 levels. The translational case for muscle maintenance and recovery follows from those hormonal changes rather than from direct muscle-outcome trials, so the frailty-specific evidence is inferential rather than direct. It is used off-label, primarily through anti-aging clinics and biohacker communities, for body composition, recovery, and sleep quality.

CJC-1295 was among the peptides the FDA reclassified in 2023, restricting it from general compounding pharmacy availability due to safety concerns and insufficient human efficacy data. That regulatory context shapes how it is currently accessed. People who used it before and after that change commonly report roughly six weeks before noticing meaningful changes in body composition and sleep, a timeline that comes up repeatedly in community accounts.

3. Ipamorelin: For Selective GH Release Without the Cortisol Spike

Ipamorelin is a synthetic pentapeptide, a five-amino-acid chain, that selectively activates ghrelin receptors in the pituitary and hypothalamus to stimulate pulsatile GH release. The word selectively is doing real work in that sentence. Most growth hormone releasing peptides raise not just GH but also cortisol and prolactin, hormones that create their own side effect burden. Ipamorelin's defining feature is a relatively clean GH pulse with minimal effect on cortisol or prolactin, which is why it is consistently cited as the preferred GHRP in anti-aging and longevity protocols, and why it has displaced older GHRPs in most community use.

In the context of frailty, it is almost always discussed alongside CJC-1295 without DAC. The logic is mechanistically sound: the two compounds hit different receptors, one the GHRH receptor and one the ghrelin receptor, and the combined signal produces greater GH release than either alone. That synergy explains why the stack is so frequently mentioned across community protocols and anti-aging clinic accounts.

Human evidence exists for ipamorelin's effects on GH and IGF-1 levels, and it has been studied enough to establish its selectivity profile. The frailty-specific human evidence, meaning direct measurement of muscle mass, physical function, or frailty scores in older adults, is limited rather than absent, and most of what gets discussed in community settings is extrapolated from its hormonal effects. User-reported experience across longevity forums describes improvements in sleep quality, recovery from exercise, and over time, body composition changes, with users noting the results feel more gradual and natural than synthetic HGH.

Like CJC-1295, ipamorelin was restricted from compounding pharmacy use under the 2023 FDA reclassification. Access runs through channels that vary by jurisdiction, and the FDA's Pharmacy Compounding Advisory Committee has a review of related peptides scheduled for mid-2026 that may shift the landscape again.

4. Follistatin 344: For Targeting Sarcopenia Directly

Follistatin 344 is the 344-amino-acid isoform of follistatin, a glycoprotein fragment that works by a completely different mechanism than anything else on this list. Rather than stimulating growth hormone, it targets the biological brake on muscle growth directly. That brake is myostatin, a protein in the TGF-beta family whose job is to limit how much skeletal muscle the body builds. Follistatin binds and neutralizes myostatin, along with related proteins called activins, effectively removing the ceiling on muscle hypertrophy.

The animal evidence for this mechanism is striking. Models engineered to lack myostatin entirely develop roughly double the normal muscle mass. That is the extreme end of the pathway. Whether injectable follistatin 344 in humans produces anything close to that effect is a different and currently unanswered question. Large-scale human trial data for frailty-specific use does not yet exist. What has been explored in research includes follistatin gene therapy, where one study showed meaningful muscle increases in older adults via that delivery method, but that is a distinct mechanism from the injectable fragment form.

In practice, follistatin 344 is used in community protocols primarily in bodybuilding and physique-focused contexts, where the myostatin inhibition appeal is obvious. Its relevance to frailty comes from the fact that sarcopenia, the progressive loss of skeletal muscle mass and strength, is one of the most central and measurable components of frailty syndrome. If you can remove the inhibition on muscle growth and pair that with adequate protein and resistance training, the mechanistic case for addressing sarcopenia is real, even where the clinical trial record in human frailty populations remains thin.

The safety picture has genuine uncertainties. Follistatin inhibits follicle-stimulating hormone alongside myostatin, which has implications for reproductive hormones. Theoretical concerns about unregulated tissue growth have not been resolved. Short cycle lengths are common in community use, partly for cost reasons and partly because of those unanswered long-term questions. The honest summary: compelling mechanism, established animal data, limited human trial record, meaningful unknowns.

5. BPC-157: For Connective Tissue and Mobility

BPC-157, Body Protective Compound-157, is a synthetic 15-amino-acid peptide derived from a protective protein originally found in gastric juice. It does not work through the GH axis at all. Its mechanism centers on tissue repair: it promotes angiogenesis, which is the growth of new blood vessels into damaged tissue, stimulates collagen synthesis, activates multiple growth factor pathways, and exerts anti-inflammatory effects across tissue types. That combination makes it the most broadly discussed healing and repair peptide in longevity communities.

For frailty, the relevant angle is connective tissue integrity. Frail individuals commonly deal with tendon, ligament, and joint degradation that limits mobility, increases fall risk, and makes exercise harder and more painful. BPC-157's value in this context is not about building muscle or raising growth hormone; it is about the tissue quality that makes movement possible and recovery from physical effort faster. Reducing nagging joint and tendon discomfort is one of the most consistently reported effects across community accounts.

The published human data is limited. Small pilot studies have established a reasonable safety profile, and the preclinical evidence for tissue repair mechanisms is among the most extensive of any compound in this space. The efficacy picture for humans rests primarily on those animal studies and a substantial volume of user-reported experience that is consistently positive for injury recovery, joint mobility, and gut health when oral formulations are used.

BPC-157 was restricted from compounding pharmacy use by the FDA in 2023. As of mid-2026, it is one of the peptides under review by the FDA's Pharmacy Compounding Advisory Committee, which is considering whether to add it to the list of bulk drug substances permitted for compounding under medical supervision. That review has not concluded, so the access situation remains in flux. It is frequently used alongside TB-500 in community protocols, the two compounds addressing complementary repair pathways.

6. SS-31: For Mitochondrial Energy Decline

SS-31, also called elamipretide, is a mitochondria-targeted tetrapeptide, a four-amino-acid chain, that works by reducing reactive oxygen species inside the mitochondria. The mitochondria are the power plants of each cell, and their declining output with age is one of the most fundamental biological underpinnings of frailty. Less efficient mitochondria mean less ATP produced per cell, which translates directly into fatigue, weakness, and reduced metabolic efficiency across the body. SS-31 targets cardiolipin on the inner mitochondrial membrane, improving energy production efficiency while reducing the oxidative stress that accumulates as mitochondria age.

What makes SS-31 distinctive among the compounds on this list is its clinical development status. It is the only compound here that has received FDA approval for a specific mitochondrial disease, Barth syndrome, which is not frailty but demonstrates it has cleared the bar for human clinical use in at least one indication. Phase III clinical trials are currently underway examining its application in heart failure, and earlier human data has explored its effects on the energy and muscle function deficits that overlap directly with frailty mechanisms. That puts it in a different evidence category than most of the other compounds here, even though frailty-specific approval does not yet exist.

Community use and discussion of SS-31 for frailty lags well behind the GH secretagogues, partly because it is a less familiar name and partly because access outside clinical trial settings is limited. Among researchers and clinicians closely following frailty biology, though, it is increasingly cited as the compound with the strongest translational argument for directly addressing the metabolic deterioration at the core of the syndrome. The evidence base is clinical rather than experiential, and it is earlier and narrower than the frailty use case requires, but it is grounded in real human trials.

7. GLP-1 Receptor Agonists: For Metabolic Frailty Progression

GLP-1 receptor agonists, including semaglutide and liraglutide, are the only entries on this list that are FDA-approved medications, though not for frailty specifically. They are approved for type 2 diabetes and obesity, and their frailty relevance comes from a different angle: a growing body of clinical data showing that older adults with type 2 diabetes who take GLP-1 medications show significantly slower progression on the Clinical Frailty Index compared to those on other diabetes medications, and this effect holds independently of cardiovascular benefits.

The mechanism connecting GLP-1 agonists to frailty is metabolic rather than anabolic. These compounds reduce cellular senescence, which is the accumulation of aged cells that stop dividing but keep releasing inflammatory signals that degrade surrounding tissue. They improve mitochondrial function. They lower chronic systemic inflammation and oxidative stress. All of those effects directly counter the biological cascade that turns metabolic decline into the physical vulnerability of frailty.

Including GLP-1 agonists here is deliberate. They represent the clearest case of a peptide-class compound with human clinical evidence for meaningful frailty-related effects. The evidence does not come from a trial designed around a frailty intervention; it comes from large-scale population data on frailty progression in people taking these drugs for other reasons. That is a real finding, and it is worth naming. For older adults who are pre-frail and metabolically compromised, the mainstream medical community's preference for these approved medications over experimental peptides reflects both the evidence base and the regulatory reality.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for frailty?

No peptide is currently FDA-approved specifically for the treatment or management of frailty. GLP-1 receptor agonists are FDA-approved for type 2 diabetes and obesity, and clinical data suggests they slow frailty progression, but frailty is not their approved indication. SS-31 is FDA-approved for a specific mitochondrial disease called Barth syndrome, not frailty. The rest of the compounds on this list are unapproved and, in several cases, restricted from compounding pharmacy use following FDA reclassification in 2023.

How do GH secretagogues differ from injectable human growth hormone?

Injectable synthetic HGH floods the body with a constant, non-pulsatile level of growth hormone, overriding the pituitary's natural rhythm entirely. GH secretagogues like MK-677, CJC-1295, and Ipamorelin work by stimulating the pituitary to produce and release its own GH in a more physiological, pulse-like pattern. Many users in anti-aging communities describe this as feeling more gradual and natural than synthetic HGH, and Ipamorelin's selectivity in particular means less interference with cortisol and other hormones. Both approaches carry their own tradeoffs, and neither is FDA-approved for frailty.

Is frailty the same as just getting old and weak?

Frailty is a recognized clinical syndrome with defined criteria, not simply a description of normal aging. It involves measurable decline across multiple systems at once: skeletal muscle loss called sarcopenia, declining physical performance, unintentional weight loss, exhaustion, and low activity levels. What makes it a syndrome rather than ordinary aging is that these changes compound each other, leaving frail individuals disproportionately vulnerable to stress events like illness, falls, or surgery. The peptide conversation around frailty is essentially a conversation about intervening in those specific biological mechanisms before they cascade.

Why is follistatin 344 included when there are no human frailty trials for it?

Because people are using it and discussing using it for sarcopenia, which is the central physical component of frailty, and that is the inclusion criterion for this list. Including it does not mean claiming it works; it means being honest that it is part of the real conversation. The entry describes the evidence accurately: strong animal data, a compelling mechanism targeting muscle loss directly, and a human trial record that does not yet exist for frailty-specific applications. Omitting it would make this list less useful to anyone already researching their options.

What did the 2023 FDA reclassification mean for accessing these compounds?

The 2023 FDA reclassification restricted several peptides, including CJC-1295, Ipamorelin, and BPC-157, from being prepared and dispensed by compounding pharmacies for general use. That changed access meaningfully for people who had been obtaining them through telehealth prescriptions filled at compounding pharmacies. As of mid-2026, the FDA's Pharmacy Compounding Advisory Committee is actively reviewing some of these compounds for possible inclusion on a bulks list that would restore compounding access under medical supervision, but those reviews have not concluded. Anyone seeking these compounds should work with a licensed physician and verify the current regulatory status in their jurisdiction.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for frailty in one place.